维迪西妥单抗治疗表达HER-2的局部晚期或转移性实体瘤的临床观察
Clincal observation of vidextus for HER-2 expressing locally advanced or metastatic solid tumors
张桂芳 1周林静 1何秋立 1李彬 1梁嘉欣1
作者信息
- 1. 453000 河南新乡 新乡市中心医院 新乡医学院第四临床学院肿瘤内科
- 折叠
摘要
目的 探讨维迪西妥单抗在表达人表皮生长因子受体(HER-2)的局部晚期或转移性实体瘤中的疗效和安全性.方法 收集 2021 年 10 月至 2023 年 11 月接受维迪西妥单抗治疗的晚期实体瘤患者 43 例,所有患者的HER-2 免疫组化(IHC)表达至少为+.入组患者均接受维迪西妥单抗单药或联合治疗,直至出现无法耐受的不良反应或疾病进展.评价患者的有效率(RR)、疾病控制率(DCR)、无进展生存期(PFS)和安全性.结果 入组的 43 例患者中,获部分缓解(PR)17 例(39.5%)、稳定(SD)15 例(34.9%)、进展(PD)11 例(25.6%).RR为 39.5%,DCR为 74.4%.在 HER-2 IHC(+/++)亚组中,RR 为 36.4%;在 HER-2 IHC(+++)亚组中,RR 为 42.9%.全组中位PFS为 4.4 个月,不同HER-2表达和不同治疗线数的患者中位PFS的差异无统计学意义(P>0.05).骨髓抑制是最常见的不良反应,最常见的 3 级不良反应为贫血和中性粒细胞减少,无 4 级不良反应或死亡发生.结论 维迪西妥单抗在表达HER-2 的局部晚期或转移性实体瘤中显示出良好的疗效和可控的安全性.
Abstract
Objective To explore the efficacy and safety of vidextus in patients with locally advanced or metastatic solid tumours expressing human epidermal growth factor receptor 2(HER-2).Methods From October 2021 to November 2023,43 patients with advanced solid tumours treated with vidextus were retrospectively reviewed.All patients had HER-2 immunohistochemical expression of at least+,and all the patients received vidextus monotherapy or combination therapy until intolerable adverse effects or disease progression occurred.Patients were evaluated for responce rate(RR),disease control rate(DCR),progression-free survival(PFS)and safety.Results In the 43 patients receiving vidextus,there were 17 cases(39.5%)of partial remission(PR),15 cases(34.9%)of stable disease(SD)and 11 cases(25.6%)of progressive disease(PD).The RR was 39.5%,and the DCR was 74.4%.In the HER-2 IHC(+/++)subgroup,the RR was 36.4%.In the HER-2 IHC(+++)subgroup,the RR was 42.9%.The median PFS was 4.4 months,the difference of median PFS in patients with different HER-2 expression or treatment was not significant(P>0.05).Safety analysis showed that myelosuppression was the most common adverse effect,and the most common grade 3 adverse effect was anaemia and neutropenia.No grade 4 adverse effect or death occured.Conclusion Vidextus showed good efficacy and a manageable safety profile in patients with locally advanced or metastatic solid tumours expressing HER-2.
关键词
实体瘤/维迪西妥单抗/抗体偶联药物/疗效/不良反应Key words
Solid tumors/Vidextus/Antibody-drug conjugates/Efficacy/Adverse effect引用本文复制引用
出版年
2024
NETL
NSTL
万方数据